Directed new share issue in Egetis Therapeutics AB (SE) — SEK 210 million

Carnegie acted as joint bookrunner in Egetis’ directed new share issue of 35,000,000 shares at a subscription price of SEK 6.0 per share. Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment.
January 2023